2010 Fiscal Year Final Research Report
Fundamental investigation aimed at EB virus-targeted therapy for nasal NK/T-cell lymphoma.
| Project/Area Number |
20390438
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
HARABUCHI Yasuaki Asahikawa Medical College, 医学部, 教授 (80208686)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKAHARA Miki 旭川医科大学, 医学部, 助教 (50322904)
KISHIBE Kan 旭川医科大学, 医学部, 助教 (80447101)
KOBAYASHI Hiroya 旭川医科大学, 医学部, 講師 (90280867)
KATAYAMA Akihiro 旭川医科大学, 医学部, 助教 (40374805)
NAGATO Toshihiro 旭川医科大学, 大学病院, 医員 (80431419)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | 鼻性NK / T細胞リンパ腫 / Epstein-Barr virus / LMP1(latent membrane protein 1) / IP-10 (Interferon gamma-induced protein-10) / monocytes / 浅側頭動脈動注・放射線同時併用療法 |
|---|
| Research Abstract |
Nasal NK/T cell lymphoma is Epstein-Barr virus(EBV)-related and poor prognosis malignancy. In this study, we found that chemokine IP-10 (Interferon gamma-induced protein-10) was produced by EBV positive Nasal NK/T cell lymphoma cell lines, and the IP-10 enhanced invasive potential of the cells in autocrine manner. Moreover, we revealed that monocytes attracted by IP-10 enhanced proliferation and LMP-1 expression of the cells by cell-contact manner via membrane-bound IL-15. Currently, we are studying about CD70 and LFA-1, which can be regulated by EBV. On clinical studies, we are trying arterial infusion chemotherapy from superficial temporal artery in combination with radiotherapy for early stage nasal NK/T-cell lymphoma. Effect of the treatments was evaluated by serum EBV-DNA copy number, as well as local findings, CT, and MRI. All of 9 patients treated by this approach were in complete remission, and no sign of relapse has seen in the patients.
|
